Maharashtra-based animal health company Sequent Scientific has guided for ₹4,000 crore revenue by FY27 with 20%+ earnings before interest, taxes, depreciation, and amortisation (EBITDA) margins.

The company is in focus after the NCLT cleared its merger with Viyash Lifesciences. Sequent operates in animal health with APIs, formulations, and product distribution, while Viyash focuses on APIs, US formulations, and emerging CDMO work.

Hari Babu, Group CEO of Sequent Scientific –Viyash Lifesciences, said the next three years will see steady growth in both APIs and formulations, but from year four onward, formulation growth will accelerate.

He added that human health margins are already stronger, while Sequent's margins have steadily improved over the past four quarters. API growth is expec

See Full Page